CK2/ERK8-IN-1
|
|
|
- CAS号:
- 1085822-09-8
- 英文名:
- CK2/ERK8-IN-1
- 英文别名:
- CK2/ERK8-IN-1;1H-Benzimidazole-1-acetic acid, 4,5,6,7-tetrabromo-2-(dimethylamino)-
- 中文名:
- CK2/ERK8-IN-1
- 中文别名:
- 化合物 T10827;化合物CK2/ERK8-IN-1
- CBNumber:
- CB38054352
- 分子式:
- C11H9Br4N3O2
- 分子量:
- 534.82
- MOL File:
- 1085822-09-8.mol
|
|
|
CK2/ERK8-IN-1化学性质
-
沸点:
-
588.8±60.0 °C(Predicted)
-
|
-
密度:
-
2.40±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: 25 mM
-
|
-
形态:
-
A crystalline solid
-
|
-
酸度系数(pKa):
-
3.43±0.10(Predicted)
-
|
CK2/ERK8-IN-1性质、用途与生产工艺
CK2/ERK8-IN-1 是一种酪蛋白激酶 2 (CK2) (Ki 为 0.25 µM) 和 ERK8 (MAPK15, ERK7) 的双重抑制剂，IC50 均为 0.50 μM。CK2/ERK8-IN-1 还与 PIM1，HIPK2 和 DYRK1A 结合，Ki 值分别为 8.65 µM，15.25 µM 和 11.9 µM。CK2/ERK8-IN-1 具有促凋亡 (pro-apoptotic) 作用。
|
CK2
0.5 μM (IC
50
)
|
CK2
0.25 μM (Ki)
|
ERK8
0.5 μM (IC
50
)
|
PIM1
8.65 μM (Ki)
|
HIPK2
15.25 μM (Ki)
|
DYRK1A
11.9 μM (Ki)
|
Apoptosis
|
CK2/ERK8-IN-1 (Compound K66; 0-50 µM; 24 hours; Jurkat cells) treatment displays cytotoxic activity in Jurkat cells.
Cell Viability Assay
|
Cell Line:
|
Jurkat cells
|
|
Concentration:
|
0-50 µM
|
|
Incubation Time:
|
24 hours
|
|
Result:
|
Inhibited cell growth in a dose-dependent manner.
|
CK2/ERK8-IN-1
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-135906 | CK2/ERK8-IN-1
CK2/ERK8-IN-1 | | 5 mg | 500元 |
| 2024/04/30 | HY-135906 | 暂无
CK2/ERK8-IN-1 | 1085822-09-8 | 10mM * 1mLin DMSO | 588元 |
1085822-09-8, CK2/ERK8-IN-1 相关搜索:
- 抑制剂
- 化合物CK2/ERK8-IN-1
- 化合物 T10827
- 1085822-09-8
- 1H-Benzimidazole-1-acetic acid, 4,5,6,7-tetrabromo-2-(dimethylamino)-
- CK2/ERK8-IN-1